|Year : 2022 | Volume
| Issue : 3 | Page : 211-214
Report of national webinar on reverse pharmacology
Bharat Rathi, Rajkumar Gupta
Center of Excellence for Pre-clinical Safely and Efficacy, Interdisciplinary Research & Therapy Evaluation, Datta Meghe Institute of Medical Sciences (Deemed to be University), Wardha, Maharashtra, India
|Date of Submission||27-Aug-2022|
|Date of Acceptance||19-Sep-2022|
|Date of Web Publication||30-Sep-2022|
Department of Rasashastra & Bhaishajya Kalpana, Mahatma Gandhi Ayurveda College Hospital & Research Center, Salod(H) Wardha, Maharashtra
Source of Support: None, Conflict of Interest: None
|How to cite this article:|
Rathi B, Gupta R. Report of national webinar on reverse pharmacology. J Indian Sys Medicine 2022;10:211-4
The National webinar was organized by the Center of Excellence for Pre-clinical Safely and Efficacy, Interdisciplinary Research and Therapy Evaluation, Datta Meghe Institute of Medical Sciences (Deemed to be University) Sawangi (Meghe) Wardha, India. The Webinar was conducted on August 22, 2022. A total of 157 participants registered and attended the webinar on the Zoom meeting platform. The Webinar was organized with the following objectives.
- To deliver comprehensive knowledge of principles of Reverse Pharmacology that is essential for the use of safe and effective evidence-based drugs in humans.
- To critically review published scientific literature related to Reverse Pharmacology studies.
- To understand and interpret guidelines with regard to clinical, pre-clinical trials, and drug research, and to develop protocol study design through a Reverse Pharmacology approach.
The webinar commenced at 10.30 AM with Dhanvantari Stavan by PG scholar Dr. Mansi Chunchuwar (prayer of Lord Dhanwantari) followed by a welcome and introductory speech by Dr. Bharat Rathi, organizing chairman who in brief explained the aim, objectives, and need of the webinar. The morning session was conducted by Dr. Bhagyashri Jibkate, assistant professor, Department of Rasashastra, Mahatma Gandhi Ayurved College, Hospital and Research Centre (MGACH-RC).
In the morning session, Hon’ble Dr. Vedprakash Mishra, Pro-Chancellor, Datta Meghe Institute of Medical Sciences (Deemed to be University) Sawangi (Meghe) Wardha in his inaugural address stressed the importance of herbal drugs and the Ayurveda system of medicine in health care. He emphasized the need and appropriateness of the selection of the topic for the webinar. He pointed out that Traditional medicine emerges as a boon for the populations in the absence of alternative or complementary medicines. He expressed concern about cost, lengthy timeline, and accessibility issues resulting from the conventional drug discovery process and appealed to the Ayurveda scholars to take advantage and to be involved in drug research through Reverse Pharmacology approaches. He also expressed the need for experiential, exploratory, and experimental research for the safety and efficacy of herbal drug development. He quotes Acharya Charaka’s famous statement that there is no medication on the planet that has no therapeutic value if we know how to use it [Figure 1].
Dr. Nilima Kshirsagar, eminent clinical pharmacologist, and former Dean, of KEM Hospital, Mumbai delivered a Keynote address from London. Madam emphasized drug development, opportunities, challenges, and strategies at length [Figure 2]. The first session was concluded by another guest speaker, Dr. Ashwini Kumar Raut, Director, Clinical Research and Integrative Medicine, Kasturba Health Society, Mumbai. He focused on the concept, precept, and prospect of Reverse Pharmacology. He has presented three success stories of herbal drugs Amrit Bhallataka tablet, Shinshapa (Dalbergia sissoo Roxb.), and Kutki (Picrorhiza kurroa Linn.) following all the three stages of Reverse Pharmacology and drug toxicity study [Figure 3].
Later Dr. Bharat Rathi, organizing chairman, introduced the audience to Certificate Course on Reverse Pharmacology initiated by the Center of Excellence, DMIMS(DU) commencing from this academic session. The course unique of its kind will be of 3 months’ duration with an intake capacity of 10. Under Graduate and Post Graduate students in any branch of life sciences passed with a minimum of 50% marks are eligible for admission to this certificate course [Figure 4].
Post lunch session began with a speech by Dr. Rajkumar Gupta, Professor, Dept of Dravyaguna, Mahatma Gandhi Ayurveda College Hospital and Research Centre Salod(H) Wardha on the first stage of Reverse Pharmacology, that is, “Selection of Herbal Remedy.” To achieve this, he stressed the need for an extensive literature search through standard ancient literature like Samhitas, Nighantus, and other Dravyaguna texts and interviews with traditional healers. He also explained the Retrospective Treatment outcome study (RTO). Clinical information on the presentation and progression of a defined disease episode is collected retrospectively for the RTO study. Further treatment and clinical outcomes are statistically evaluated [Figure 5]. The session was chaired by Dr. Anita Wanjari, Professor and Head, Dept of Rasashastra and Bhaishajya Kalpana who gave her expert comments.
The IInd Stage of Reverse Pharmacology––“Dose Escalating Study (D.E.S.)” is presented by Dr. Shailesh Nagpure, Professor, Department of Pharmacology, JNMC, Wardha. He explained the purpose of D.E.S. to find out the best effective dose with minimum side effects of the drug. The drug is used by the patient but no literature is available, in such case, a pilot study in which an observational clinical study in small groups of patients with three dosages is to be conducted and the best effective dose is to be taken for conducting RCTs. He has explained the aim, initial requirement, protocol contents, volunteer selection, study design and risk/adverse events that occur during the D.E.S. He also explained the mathematical methods and stages of D.E.S. [Figure 6]. The session was chaired by Dr. Deepak Khobragade, Associate Professor, Dept of Pharmaceutics, Datta Meghe College of Pharmacy, Wardha. The session concluded with an expert remark by the chair.
Stage III of Reverse Pharmacology i.e. Randomized Controlled Trials (RCTs) is well explained by Dr. Swanand Pathak, Professor, and Head, Department of Pharmacology, JNMC, Wardha. In RCT, the best effective dose obtained from the Pilot study is to be taken for conducting RCTs to establish safety and efficacy. He cited various examples for a better understanding of the concept. He also explained key study designs and steps, key elements of RCTs, and the CONSORT Flow diagram [Figure 7]. This session was chaired by Dr. Asha Jha, Professor, Dept of Pharmacology, JNMC, Wardha. At the end of the session, a brief question-answer session was conducted which was well answered by the speakers and Dr. S.S. Patel, Director, Center of Excellence [Figure 8].
The last part of the webinar was the Valedictory function, which was conducted by Dr. Bhagyashri Jibkate, assistant professor, Department of Rasashastra, MGACH, and RC. Dr. Bharat Rathi, Organizing Chairman presented a brief summary of the webinar. Feedback was taken from the participants, which was satisfactory. Finally, the webinar was concluded with a Vote of Thanks by Dr. Pranjali Dukare, PG Scholar, Department of, MGACH and RC.
In nutshell, a thorough discussion is done on the concept of Reverse Pharmacology which benefited the budding researchers, faculties, and Ph.D. scholars. Dr. Mujahid Khan, associate professor, Dr. Akshay Pargaonkar, assistant professor, and Mr. Pranay Thool, executive assistant, Center of Excellence worked hard for the successful organization of the webinar [Figure 9].
| Glimpses of the National Webinar on Reverse Pharmacology|| |
The authors are thankful to Dr. S. S. Patel, Director, Center of Excellence for Pre-clinical Safely and Efficacy, Interdisciplinary Research and Therapy Evaluation, DMIMS (DU) for his untiring support and guidance for the conduction of the Webinar.
Financial support and sponsorship
The study was supported by Center of Excellence, DMIMS (DU).
Conflicts of interest
There are no conflicts of interest
[Figure 1], [Figure 2], [Figure 3], [Figure 4], [Figure 5], [Figure 6], [Figure 7], [Figure 8], [Figure 9]